[How I treat acquired clotting factor deficiency].

Area of Science:

• Hematology
• Internal Medicine
• Clinical Pathology

Background:

• Acquired clotting factor deficiency presents diverse etiologies, including inhibitors, liver disease, and DIC.
• Acquired clotting factor inhibitors are rare, posing diagnostic and therapeutic challenges.
• Standardized management protocols are crucial for effective patient care.

Purpose of the Study:

• To provide practical guidance for the standardized management of acquired clotting factor deficiencies.
• To highlight diagnostic and therapeutic strategies for rare acquired clotting factor inhibitors.
• To integrate clinical cases for enhanced understanding and application of management principles.

Main Methods:

• Review of clinical cases and existing literature on acquired clotting factor deficiencies.
• Analysis of diagnostic challenges and therapeutic approaches for acquired inhibitors.
• Integration of data to formulate practical management guidelines.

Main Results:

• Acquired clotting factor inhibitors represent a rare but significant cause of bleeding disorders.
• Effective management hinges on early bleeding recognition, individualized therapy, and continuous monitoring.
• Standardized protocols, like those for acquired hemophilia A in China, are essential, though data on other inhibitors remain limited.

Conclusions:

• Standardized management of acquired clotting factor deficiencies, particularly rare inhibitors, is critical.
• Treatment should focus on achieving hemostasis and eradicating inhibitors, utilizing novel therapies for refractory cases.
• This article offers practical guidance based on integrated clinical experience to improve patient outcomes.